Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05685030
Other study ID # 63543922.2.0000.0119
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 5, 2023
Est. completion date July 30, 2023

Study information

Verified date January 2023
Source Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Therefore, based on data in the literature, it is understood that there is evidence of the effectiveness of using probiotics, either alone or in the form of a blend, to alleviate the symptoms of infantile colic.


Description:

Infantile colic represents a self-limiting temporary condition, which occurs in about one in five babies in the first few months of life, and is characterized by inconsolable crying and fussiness of unknown cause. Despite its benign nature, infantile colic serves as a significant source of maternal anxiety and depression, impaired family functioning, and the most common reason for seeking medical advice in this age group. Infant colic is also associated with sleep problems in babies. Parents and caregivers often seek medical attention for colic, including the use of medication, plant fiber, lactase, sucrose solution, hypoallergenic diet, and herbal tea. However, there is no single effective and safe intervention for infantile colic. Interest in the use of probiotics as a potential treatment to reduce crying in babies with colic has increased lately. Recent studies have reported that the gut microbiota in infants with colic is characterized by lower proportions of Lactobacilli and Bifidobacteria and higher proportions of opportunistic proteobacteria (such as Escherichia coli, Enterobacter aerogenes and Klebsiella spp.) in comparison with the control babies. Thus, several researchers have suggested that probiotics may be useful in treating breastfed babies with colic and reducing crying time. One study showed that administration of Lactobacillus reuteri DSM 17938 improved colic symptoms, although the effectiveness was only seen in breastfed and not formula fed infants. Another study showed that treatment with a combination of L. casei, L. rhamnosus, Streptococcus thermophilus, B. breve, L. acidophilus, B. infantiles, L. bulgaricus and fructooligosaccharides (FOS) reduced the duration of crying by almost 35 min compared to placebo. Furthermore, other authors has reported a reduced incidence of caregiver-reported colic when infants were supplemented with a combination of B. animalis subsp. lactis BB-12 and an unidentified strain of S. thermophilus, although colic was not formally diagnosed by a physician, which reduced the strength of the studies. A recent study on the same BB-12 strain overcame this deficiency by formally diagnosing colic using Rome-III criteria. However, this study showed that the response rate did not significantly improve over placebo until day 21. On the other hand, one study reported that the use of L. rhamnosus GG (ATCC53103) had no significant effect on crying in babies with colic. In another study, no significant differences were found in crying and irritability between the probiotic and placebo groups when supplemented with L. reuteri ATCC55730 or B. lactis BB-12.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date July 30, 2023
Est. primary completion date January 5, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 17 Days to 23 Days
Eligibility Inclusion Criteria: - Age 20 days ± 3 days. - Informed consent form signed by parents - Both gender - Availability to complete scales daily and answer phone calls and/or text messages. Exclusion Criteria: - Birth weight <2500 g; - current intake of antibiotics, prebiotics, or probiotics by the baby or mother; - Children with known moderate or severe disease of any system (neural, skeletal, muscular, cutaneous, gastrointestinal, respiratory, genital, urinary, immune), - parental difficulty in understanding study requirements as judged by physician.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Placebo
product vehicle (sunflower oil)
Limosilactobacillus reuteri CCT 7862
Limosilactobacillus reuteri CCT 7862 - 1 x 10e9 UFC/ day.
Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863
Bifidobacterium lactis CCT 7858 + Lactobacillus rhamnosus CCT 7863 - 1 x 10e9 UFC/ day

Locations

Country Name City State
Brazil Monique Michels Criciuma Santa Catarina

Sponsors (1)

Lead Sponsor Collaborator
Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of probiotics strains by total daily crying time Efficacy of probiotics strains by total daily crying time (minutes for day) recorded by parents daily Change from baseline at three months
Primary Efficacy of probiotics strains by total daily agitation time Efficacy of probiotics strains by total daily agitation time (minutes for day) recorded by parents daily Change from baseline at three months
Secondary Safety and Efficacy of probiotics strains Safety and Efficacy of probiotics strains by baby sleep duration (minutes for day) and and sleep quality through scale recorded by parents daily. This Score use a four-point, Likert-type scale, respondents indicate how frequently they exhibit certain sleep behaviors (0 = "few," 1 = "some- times," 2 = "often," and 3 = "almost always"). Change from baseline at three months
Secondary Safety and Efficacy of probiotics strains Safety and Efficacy of probiotics strains by daily frequency evacuation and stool consistency (Bristol scale). There are seven types of stools (faeces) according to the Bristol Stool Chart. Type 1-2 indicate constipation, Type 3-4 are ideal stools as they are easier to pass, and Type 5-7 may indicate diarrhoea and urgency. Change from baseline at three months
See also
  Status Clinical Trial Phase
Completed NCT01849991 - Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic Phase 1
Completed NCT01279265 - Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic N/A
Completed NCT00177086 - Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Phase 3
Not yet recruiting NCT02577133 - Prevention of Colic With the Probiotic Lactobacillus Reuteri Phase 2/Phase 3
Recruiting NCT01715220 - Treatment of Suspected Cholelithiasis With Nitroglycerin Phase 2
Completed NCT00922727 - Safety of Lactobacillus Reuteri (L. Reuteri) in Healthy Adults Phase 1
Completed NCT02865564 - Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics N/A
Completed NCT01997593 - Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected Phase 2
Completed NCT01541046 - Lactobacillus Reuteri DSM 17938 Versus Placebo in the Treatment of Infantile Colic Phase 2
Completed NCT00929292 - Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic Phase 3
Recruiting NCT05554991 - Human Milk Oligosaccharide (HMO) Supplementation in Colic Management N/A
Recruiting NCT01067027 - Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri Phase 4
Recruiting NCT04983069 - Neonatal Outcome of Children With Antenatal Colic Hyperechogenicity
Withdrawn NCT05198700 - The Effect of Probiotics on Symptoms of Infantile Colic Phase 2
Terminated NCT02586558 - Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants N/A
Completed NCT01532518 - Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance Phase 2
Completed NCT00796523 - An Intervention to Decrease Infant Crying N/A
Completed NCT05052476 - First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic N/A
Completed NCT02242292 - Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort Phase 2
Terminated NCT00139646 - Parecoxib in Renal Colic Phase 3